<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39386973</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1920-2903</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>4</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>The Canadian journal of hospital pharmacy</Title><ISOAbbreviation>Can J Hosp Pharm</ISOAbbreviation></Journal><ArticleTitle>Glycemic Management in Patients with COVID-19 Admitted to the Intensive Care Unit: Evaluation of Glycemic Control and Drug Therapy.</ArticleTitle><Pagination><StartPage>e3553</StartPage><MedlinePgn>e3553</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e3553</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4212/cjhp.3553</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Emerging evidence describes the high incidence and strong impact of hyperglycemia on the outcomes of critically ill patients with a diagnosis of COVID-19. Given resource limitations during the COVID-19 pandemic, clinicians moved away from using continuous IV infusions of insulin to manage hyperglycemia.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate glycemic control in critically ill patients receiving various medication regimens to manage their hyperglycemia.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This retrospective cohort study involved 120 mechanically ventilated adult patients (&gt; 18 years) with COVID-19 who were admitted to the intensive care unit (ICU) between February 2020 and December 2021. The following data were collected for the first 14 days of the ICU admission: blood glucose values (up to 4 times daily), hypoglycemia events, and antihyperglycemic medication regimens.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The use of IV insulin infusions maintained glucose measurements within the target range of 4 to 10 mmol/L more often than any other medication regimen, with 60% of measured values falling within the target range. The use of a sliding-scale insulin regimen maintained 52% of glucose measurements within the target range. Oral hypoglycemic agents performed relatively poorly, with only 12% to 29% of glucose measurements within range. The coadministration of corticosteroids led to worse glycemic control across all medication regimens.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This study confirmed that ICUs should continue using the standard protocol of IV insulin infusion to achieve recommended blood glucose targets in critically ill patients with COVID-19, particularly those receiving corticosteroids.</AbstractText><CopyrightInformation>2024 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blacklaws</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>, BSc, PharmD, was, at the time of this study, a student in the Entry-to-Practice PharmD program, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia. She has now graduated and is currently a Year 1 pharmacy resident with Lower Mainland Pharmacy Services in British Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Kieran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>, BSc(Pharm), ACPR, PharmD, is a Clinical Pharmacy Specialist (Critical Care), Surrey Memorial Hospital, Surrey, British Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stabler</LastName><ForeName>Sarah N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>, BSc(Pharm), ACPR, PharmD, is a Clinical Pharmacy Specialist (Critical Care) with Surrey Memorial Hospital, Surrey, British Columbia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Can J Hosp Pharm</MedlineTA><NlmUniqueID>0215645</NlmUniqueID><ISSNLinking>0008-4123</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="fre"><AbstractText Label="CONTEXTE" NlmCategory="UNASSIGNED">Des données probantes émergentes font état de l’incidence élevée et des fortes répercussions de l’hyperglycémie sur les résultats des patients gravement malades ayant reçu un diagnostic de COVID-19. Vu les ressources restreintes pendant la pandémie de COVID-19, les cliniciens se sont éloignés de l’utilisation des perfusions continues d’insuline par IV pour gérer l’hyperglycémie.</AbstractText><AbstractText Label="OBJECTIF" NlmCategory="UNASSIGNED">Évaluer le contrôle glycémique chez les patients gravement malades qui reçoivent divers régimes médicamenteux pour gérer leur hyperglycémie.</AbstractText><AbstractText Label="MÉTHODOLOGIE" NlmCategory="UNASSIGNED">Cette étude de cohorte rétrospective portait sur 120 patients adultes (&gt; 18 ans) atteints de la COVID-19 ventilés mécaniquement ayant été admis à une unité de soins intensifs entre février 2020 et décembre 2021. Les données suivantes ont été recueillies pendant les 14 premiers jours de l’admission en USI : valeurs glycémiques (jusqu’à 4 fois par jour), événements d’hypoglycémie et régimes de médicaments antihyperglycémiants.</AbstractText><AbstractText Label="RÉSULTATS" NlmCategory="UNASSIGNED">L’utilisation de perfusions d’insuline par intraveineuse permettait de maintenir les mesures de glucose dans la plage cible de 4 à 10 mmol/L plus souvent que tout autre schéma thérapeutique, avec 60 % des mesures se situant dans la plage cible. L’utilisation d’un schéma thérapeutique à insuline à échelle mobile a permis de maintenir 52 % des mesures de glucose dans la plage cible. Les résultats des hypoglycémiants oraux étaient relativement mauvais, avec seulement 12 % à 29 % des mesures de glucose se situant dans la plage cible. L’administration concomitante de corticostéroïdes a entraîné un moins bon contrôle glycémique dans tous les schémas thérapeutiques.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Cette étude a confirmé que les unités de soins intensifs devraient continuer à utiliser le protocole standard de perfusion d’insuline par IV pour atteindre les objectifs de glycémie recommandés chez les patients gravement malades atteints de la COVID-19, en particulier ceux recevant des corticostéroïdes.</AbstractText><CopyrightInformation>2024 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">diabetes mellitus</Keyword><Keyword MajorTopicYN="N">glycemic control</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword></KeywordList><CoiStatement>Competing interests: For work not directly related to the study reported here, Kieran Shah received payment for teaching from the Columbia Paramedic Academy and has served in a non-remunerated role with the CSHP Advocacy Committee; and Sarah Stabler has received payment from the University of British Columbia for presentation of lectures. No other competing interests were declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39386973</ArticleId><ArticleId IdType="pmc">PMC11426961</ArticleId><ArticleId IdType="doi">10.4212/cjhp.3553</ArticleId><ArticleId IdType="pii">cjhp-77-e3553</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. doi: 10.1001/jama.2020.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE-SUGAR Study Investigators. Finfer S, Chittock DR, Su SYS, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–97. doi: 10.1056/NEJMoa0810625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0810625</ArticleId><ArticleId IdType="pubmed">19318384</ArticleId></ArticleIdList></Reference><Reference><Citation>Griesdale DEG, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009;180(8):821–7. doi: 10.1503/cmaj.090206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.090206</ArticleId><ArticleId IdType="pmc">PMC2665940</ArticleId><ArticleId IdType="pubmed">19318387</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063–e1143. doi: 10.1097/CCM.0000000000005337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005337</ArticleId><ArticleId IdType="pubmed">34605781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068–77e3. doi: 10.1016/j.cmet.2020.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.04.021</ArticleId><ArticleId IdType="pmc">PMC7252168</ArticleId><ArticleId IdType="pubmed">32369736</ArticleId></ArticleIdList></Reference><Reference><Citation>Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020;39:101044. doi: 10.1016/j.molmet.2020.101044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2020.101044</ArticleId><ArticleId IdType="pmc">PMC7308743</ArticleId><ArticleId IdType="pubmed">32585364</ArticleId></ArticleIdList></Reference><Reference><Citation>Somasundaram NP, Ranathunga I, Ratnasamy V, Wijewickrama PSA, Dissanayake HA, Yogendranathan N, et al. The impact of SARS-Cov-2 virus infection on the endocrine system. J Endocr Soc. 2020;4(8):bvaa082. doi: 10.1210/jendso/bvaa082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jendso/bvaa082</ArticleId><ArticleId IdType="pmc">PMC7337839</ArticleId><ArticleId IdType="pubmed">32728654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kethireddy R, Gandhi D, Kichloo A, Patel L. Challenges in hyperglycemia management in critically ill patients with COVID-19. World J Crit Care Med. 2022;11(4):219–27. doi: 10.5492/wjccm.v11.i4.219.</Citation><ArticleIdList><ArticleId IdType="doi">10.5492/wjccm.v11.i4.219</ArticleId><ArticleId IdType="pmc">PMC9305683</ArticleId><ArticleId IdType="pubmed">36051939</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813–21. doi: 10.1177/1932296820924469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1932296820924469</ArticleId><ArticleId IdType="pmc">PMC7673150</ArticleId><ArticleId IdType="pubmed">32389027</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardu C, D’Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020;43(7):1408–15. doi: 10.2337/dc20-0723.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-0723</ArticleId><ArticleId IdType="pmc">PMC7305003</ArticleId><ArticleId IdType="pubmed">32430456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazori AY, Bass IR, Chan L, Mathews KS, Altman DR, Saha A, et al. Hyperglycemia is associated with increased mortality in critically ill patients with COVID-19. Endocr Pract. 2021;27(2):95–100. doi: 10.1016/j.eprac.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eprac.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7796656</ArticleId><ArticleId IdType="pubmed">33551315</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnasamy S, Sheikh D, Ali T, Clemons V, Furmanek S, Mohamed Fawzy Abdelhaleem AA, et al. Impact of hyperglycemia on cardiovascular events and clinical outcomes in patients hospitalized with COVID-19 pneumonia. Endocr Pract. 2022;28(8):780–6. doi: 10.1016/j.eprac.2022.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eprac.2022.05.011</ArticleId><ArticleId IdType="pmc">PMC9166248</ArticleId><ArticleId IdType="pubmed">35671878</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran KK, Kibert JL, 2nd, Telford ED, Franck AJ. Intravenous insulin infusion protocol compared with subcutaneous insulin for the management of hyperglycemia in critically ill adults. Ann Pharmacother. 2019;53(9):894–8. doi: 10.1177/1060028019841363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1060028019841363</ArticleId><ArticleId IdType="pubmed">30924349</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354(5):449–61. doi: 10.1056/NEJMoa052521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa052521</ArticleId><ArticleId IdType="pubmed">16452557</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–67. doi: 10.1056/NEJMoa011300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa011300</ArticleId><ArticleId IdType="pubmed">11794168</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7):e3319. doi: 10.1002/dmrr.3319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3319</ArticleId><ArticleId IdType="pmc">PMC7228407</ArticleId><ArticleId IdType="pubmed">32233013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawshani A, Kjölhede EA, Rawshani A, Sattar N, Eeg-Olofsson K, Adiels M, et al. Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: a nationwide retrospective cohort study. Lancet Reg Health Eur. 2021;4:100105. doi: 10.1016/j.lanepe.2021.100105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100105</ArticleId><ArticleId IdType="pmc">PMC8086507</ArticleId><ArticleId IdType="pubmed">33969336</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed Z, Velásquez García HA, Wong S, Wilton J, McKee G, Mahmood B, et al. Association of COVID-19 infection with incident diabetes. JAMA Netw Open. 2023;6(4):e238866. doi: 10.1001/jamanetworkopen.2023.8866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.8866</ArticleId><ArticleId IdType="pmc">PMC10114057</ArticleId><ArticleId IdType="pubmed">37071420</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulds ER, Boutsicaris A, Sumner L, Jones L, McNett M, Smetana KS, et al. Use of continuous glucose monitor in critically ill COVID-19 patients requiring insulin infusion: an observational study. J Clin Endocrinol Metab. 2021;106(10):e4007–e4016. doi: 10.1210/clinem/dgab409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgab409</ArticleId><ArticleId IdType="pubmed">34100545</ArticleId></ArticleIdList></Reference><Reference><Citation>BC Centre for Disease Control. Respiratory virus data. Provincial Health Services Authority; 2024.  [cited 2024 Mar 6]. Available from:  http://www.bccdc.ca/health-professionals/data-reports/respiratory-virus-data#Reports.</Citation></Reference><Reference><Citation>Eslami S, Taherzadeh Z, Schultz MJ, Abu-Hanna A. Glucose variability measures and their effect on mortality: a systematic review. Intensive Care Med. 2011;37(4):583–93. doi: 10.1007/s00134-010-2129-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-2129-5</ArticleId><ArticleId IdType="pmc">PMC3058514</ArticleId><ArticleId IdType="pubmed">21279326</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>